Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy.
Breast Cancer
January 2022
Department of Surgery, Máxima Medical Centre, De Run 4600, 5500 MB, Veldhoven, The Netherlands.
Background: The aim of this study was to investigate which factors patients considered to be important for determining the degree of cosmetic satisfaction with regards to perceived body image after previous breast-conserving therapy (BCT).
Methods: Outcomes considered relevant by the patients were first identified using interviews. A questionnaire based on this group input was then devised and added to the physician-based Sneeuw questionnaire.
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry.
Drug Saf
January 2021
Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
The long-term and potential rare side effects of new immunomodulating drugs for the treatment of multiple sclerosis (MS) are often not well known. Spontaneous case report systems of adverse drug effects are a valuable source in pharmacovigilance, but have several limitations. Primary data collections within registries allow a comprehensive analysis of potential side effects, but face several challenges.
View Article and Find Full Text PDFPersonalised physician learning intervention to improve hypertension and lipid control: randomised trial comparing two methods of physician profiling.
BMJ Qual Saf
December 2014
HealthPartners Institute for Education and Research and HealthPartners Centre for Chronic Care Innovation, Minneapolis, Minnesota, USA.
Purpose: To assess the impact of personalised physician learning (PPL) interventions using simulated learning cases on control of hypertension and dyslipidaemia in primary care settings.
Methods: A total of 132 primary care physicians, 4568 eligible patients with uncontrolled hypertension, and 15 392 eligible patients with uncontrolled dyslipidaemia were cluster-randomised to one of three conditions: (a) no intervention, (b) PPL-electronic medical record (EMR) intervention in which 12 PPL cases were assigned to each physician based on observed patterns of care in the EMR in the previous year, or (c) PPL-ASSESS intervention in which 12 PPL cases were assigned to each physician based on their performance on four standardised assessment cases. General and generalised linear mixed models were used to account for clustering and to model differences in patient outcomes in the study arms.
Physician-based brand strategies.
Mark Health Serv
February 2003
Yale-New Haven Hospital, Conn., USA.
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
J Card Fail
September 2000
Mount Sinai School of Medicine and Cornell University, Weill Medical College, New York, New York, USA.
Background: The success of beta-blocking agents in clinical trials of heart failure (HF) has led to a widespread call for their increased use, which assumes these agents will perform as well in the usual care setting. Given the traditional contraindication of the use of beta-blocking agents in HF, and their perception as difficult to use in HF, observing how they perform in the usual care setting could be critical in accelerating their widespread application. Carvedilol is the only beta-blocking agent currently approved in the United States for use in HF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!